Prostate cancer is the second most frequently diagnosed type of tumour and the fifth leading cause of cancer-related deaths in men worldwide 1 . A subset of patients experience disease relapse and the development of metastases in distant organs despite undergoing watchful waiting or local therapy 2, 3 . Treatment modalities that improve the survival of patients with advanced disease include androgen withdrawal 4, 5 , taxane chemotherapy [6] [7] [8] [9] [10] , and second-generation androgen signalling inhibitors [11] [12] [13] [14] , among other therapeutic approaches including radium-223-mediated α emission 15 or active cellular immunotherapy using sipuleucel-T
. Treatment modalities that improve the survival of patients with advanced disease include androgen withdrawal 4, 5 , taxane chemotherapy [6] [7] [8] [9] [10] , and second-generation androgen signalling inhibitors [11] [12] [13] [14] , among other therapeutic approaches including radium-223-mediated α emission 15 or active cellular immunotherapy using sipuleucel-T 16 . However, advanced prostate cancer inevitably progresses to a therapy-resistant state that ultimately precedes lethality. Dissecting the molecular determinants of tumour progression to lethal prostate cancer will, therefore, stimulate new therapeutic strategies that will serve to improve the clinical outcome of patients with this disease.
The seminal studies by Huggins and Hodges in the 1940s 17, 18 showed that tumour growth and survival depends on androgen receptor (AR) signalling throughout almost all stages of disease, despite its heterogeneous nature and without a full understanding of the natural course of this disease 19, 20 . The mechanisms of disease progression to requirement for AR ablative therapy are classified as androgen-dependent (involving AR amplification or mutation) and androgen-independent (such as phosphatase and tensin homologue (PTEN) loss and RAC-α serine/threonine-protein kinase (AKT) activation). Mechanisms of progression to taxane therapy (docetaxel or cabazitaxel), the other mainstay of prostate cancer therapy, have also been extensively studied and include aberrant regulation of molecules involved in cell survival and death, overexpression of membrane efflux pumps, and modifications in the expression of the taxane target β-tubulin, among others 21 . In this Review we provide insight into the key function that endothelial transcription factor GATA-2 (GATA2), a transcription factor classically linked with haematopoiesis, exerts as a mediator of prostate cancer progression in both an AR-dependent and AR-independent manner and through the early to late stages of the disease. Whether it is via its role in regulating AR signalling as a pioneer factor, or owing to its function in driving a network of AR-independent signalling pathways, targeting of GATA2 might contribute to the development of new, much-needed therapeutic strategies for treating lethal prostate cancer.
The GATA2 transcription factor
The GATA family is a set of evolutionarily conserved genes that encode pioneer transcription factors, which regulate the development and differentiation of diverse tissues in eukaryotic organisms [22] [23] [24] . The family owes its name to their ability to bind specific DNA consensus sequences containing the GATA sequence (A/T-GATA-A/G) through two highly conserved zinc finger motifs 25, 26 . In mammals, the GATA family contains six proteins, GATA1-GATA6, which in turn can be grouped into two subfamilies: GATA1-GATA3 are mostly involved in haematopoietic cell fate, and GATA4-GATA6 are implicated in endodermal and cardiovascular development 23, 27, 28 (FIG. 1a) .
Most nuclear DNA is inaccessible owing to nucleosomal chromatin organization, leaving the vast majority of DNA-binding sites for transcription factors unoccupied, as has been shown using genome-wide location analyses 29 . In this context, pioneer transcription factors are characterized by their special ability to bind directly to these DNA regions of 'closed' chromatin, which is inaccessible to other factors, at some point before transcriptional activation. They either gain access passively or actively by opening and reorganizing chromatin, facilitating subsequent hierarchical binding of other regulators (transcription factors, cofactors, chromatinmodifying, and remodelling proteins) and activating gene expression 30 (FIG. 1b) .
This nucleosome-binding ability is deemed essential for triggering transcription activation at otherwise silent chromatin sites that act as master regulators of signalling networks 31 . Interestingly, pioneer transcription factors might cooperate to achieve gene expression regulation, as shown by the close association between GATA and forkhead box protein A1 (FOXA) families in their role establishing temporal gene expression patterns in the undifferentiated gut endoderm 32, 33 .
GATA2 function in development
GATA2 was first demonstrated to be a critical component in the proliferation and differentiation of early haematopoietic progenitors and it has long been known to be an indispensable haematopoietic transcription factor 34, 35 . Early loss-of-function studies showed that mice bearing null mutations at the GATA2 locus developed severe anaemia early in embryo genesis, and, therefore, provided the first strong evidence that GATA2 involvement is fundamental to primitive haematopoiesis 34, 35 . This evidence correlates with the observation that the emergence of definitive haematopoietic stem cells (HSCs) is dependent on the activation of GATA2 through neurogenic locus notch homologue protein 1 (NOTCH1) 36, 37 , which is fundamental for cell fate establishment and classically linked with haematopoietic development, among several other upstream regulators such as stem cell leukaemia protein (SCL), LIM domain only 2 protein (LMO2) and runt related transcription factor 1 protein (RNX1) 36 . Consequently, an interruption of the GATA2 signalling cascade results in an impairment of primary haematopoiesis, causing anaemia, decreased thrombopoiesis, and embryonic death owing to haematopoietic failure 24 . Moreover, GATA2 is mainly expressed in HSCs, early haematopoietic precursor cells (HPCs) and erythroid precursors, but its levels gradually decline as cells undergo differentiation and proliferation, and other factors such as GATA1 are eventually required for terminal maturation 38 . However, this decline in expression does not mean that GATA2 is absent in haematopoietic tissues of adult organisms 39, 40 , as GATA2 continues to have an important role in the maintenance of HSCs in the bone marrow of adults 41 . Given that GATA2 expression is especially observed in early progenitor cells, its implication in vascular development (especially through regulation of the commitment of haemangioblasts 42 -multipotent cell precursors that can differentiate into both endothelial cells and HPCs during normal vertebrate development) is not surprising 42, 43 . The common origin of endothelial cells and HPCs indicates that several transcription factors involved in the differentiation of haemangioblasts to the blood lineage can also regulate their differentiation in to endothelial cells 44 . Indeed, GATA2 has been shown to bind and regulate the promoter activity of several endothelium-specific genes, including PECAM1 (REF. 45 ) and EDN1 (REF. 46 ), in addition to regulating the expression of VEGFR2 (also known as KDR) during both vascular development and angiogenesis 47, 48 . The central role that GATA2 has in early development hindered the investigation of its potential functions in later stages of development, owing to embryonic mortality in GATA2-null mice (as a result of an impairment in primitive haematopoiesis), and, therefore, masked the sequelae of GATA2 ablation in these mice 49 .
The critical role of GATA2 in urogenital development was revealed when GATA2-null mice were rescued using a yeast artificial chromosome (YAC) transgene 49 . YAC-rescued GATA2-null mice survived embryonic development but succumbed to lethal hydronephrosis and displayed a complex array of genito urinary abnormalities that resulted in postnatal mortality 49 . Further analysis revealed that GATA2 is indeed expressed in embryonic structures that give rise to the urogenital
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Role of GATA2 in prostate cancer
The role of GATA2 in the pathogenesis of prostate cancer is of increasing interest, owing to the observation that it is a major contributor to the development of the urogenital and haematopoietic systems. GATA2 is involved in the pathogenesis of malignancies originating in organs in these systems. For example, heterozygous mutations in GATA2 are associated with a broad spectrum of haematological disorders [52] [53] [54] [55] [56] leading to the hypothesis that GATA2 expression might also contribute to the development and progression of prostate cancer (FIG. 2) . GATA2 is a critical component in the complex regulatory network of transcription factors that sustains prostate cancer growth in both AR-dependent prostate cancer and castration-resistant prostate cancer (CRPC), in which it acts as a supporter and mediator of AR signalling 57, 58 . Aside from this well-characterized role, data demonstrate that GATA2 further contributes to the lethal progression of CRPC in an AR-independent manner 59 . Computational analysis of the gene expression profiles of paired metastatic and nonmetastatic prostate cancer xenografts identified GATA2 as a potential regulator of metatasis 60 . Moreover, GATA2 silencing using small interfering RNA in LNCaP cells showed a decrease in cell migration and tissue invasion. GATA2 silencing resulted in persistence of focal adhesion complexes, indicating that it has a crucial role in focal adhesion disassembly. Genes associated with prostate cancer progression and metastasis, including FOXM1, c-MYC, UHRF1, EZH2, BMP6, AURKA, and BIRC5 were also downregulated in GATA2-silenced LNCaP cells 61 . Notably, increased GATA2 mRNA and protein expression in tissue samples from patients with clinically localized prostate cancer was significantly associated with increased Gleason score and tumour stage (P = 0.008 and P = 0.001, respectively) 62 and an increased probability of disease relapse and developing distant metastasis [61] [62] [63] . GATA2 mRNA and protein levels were higher in samples from metastatic sites than primary tumour specimens 59, 61, 62 . This evidence suggests that GATA2 is a novel target for the treatment of prostate cancer.
GATA2 and androgen-dependent prostate cancer. The androgen-dependent stage of prostate cancer is arguably one of the earliest stages of disease progression 19, 20 and is defined by a marked dependence on androgens for cell survival and tumour growth. In this disease stage, the AR and its co-activators bind to canonical AR regulatory elements in genes such as PSA (also known as KLK3), which is upregulated in prostate cancer 64 , and TMPRSS2, which can fuse with the oncogenes ERG or ETV1 and can mediate their androgen-responsive overexpression in prostate tumours 65 . GATA2 regulates the metastatic potential of prostate cancer cells in the early stages of disease through various regulatory mechanisms. GATA2 has been shown to increase the metastatic potential of androgenresponsive LNCaP cells. In vitro, AZGP1 expression was decreased in GATA2-overexpressing LNCaP cells on treatment with 5α-dihydroxytestosterone 63 . Decreased AZGP1 has been reported as a strong predictor of poor clinical outcomes in men with prostate cancer 66 . GATA2-mediated and AR-mediated changes in gene expression in prostate cancer suggest that crosstalk between both of these transcription factors has an essential role in androgen-dependent prostate cancer 57, 58, 63, 67 . Discerning the role of GATA2 in earlystage prostate cancer could have major implications Nature Reviews | Urology for understanding disease progression and is a new avenue for research in this area. Wu and colleagues 58 observed that GATA2 acts as a pioneer factor that drives androgen-responsive gene expression through a threetiered role acting at a genome-wide level. Firstly, it binds to an upstream promoter region of AR regulatory elements and enhances basal and androgen-stimulated AR expression. Secondly, GATA2 mimics FOXA1 function in creating an accessible chromatin environment and establishes an accessible local chromatin environment in AR enhancers by recruiting p300, a histone acetylase transferase (HAT) that activates chromatin via acetylation of H3K27 (REFS 58, 68) . Finally, it forms and maintains regulatory chromatin loops between AR-bound distal enhancers and AR-target-gene promoters via recruitment of the mediator co-regulatory complex subunit MED1 (REF. 58 ). GATA2, as a pioneer transcription factor, is required for AR binding to PSA, TMPRSS2, and PDE9A enhancers and has been suggested to be a critical factor in a theoretical hierarchical regulation network that could drive androgen-dependent, AR-target-gene expression 57 . It participates in a complex interaction between transcription factors, notably POU domain, class 2, transcription factor 1 (POU2F1, also known as OCT1) and FOXA1 (REFS 57, 58) . POU2F1 exerts its function subsequent to GATA2 and acts with AR and is, therefore, not considered a pioneer factor necessary for AR-mediated expression of PSA or TMPRSS2 (REF. 67 ). However, FOXA1 co-occupies AR-target-gene enhancers with GATA2 -GATA motifs and GATA2 binding events are considerably enriched in parallel with FOXA motifs and FOXA1 binding events within these regulatory regions 57, 58 . Sequence analyses of AR, GATA2, and FOXA1 using chromatin immunoprecipitation showed that GATA2 and AR strongly enhance each other's transcriptional programmes and that FOXA1 regulates the cistromes of not only AR but also GATA2, acting, therefore, as a pioneer factor for both 69 .
Collectively, these studies demonstrate that GATA2 is part of a complex hierarchical network of transcription factors that regulate AR signalling in the setting of androgen-dependant prostate cancer, and highlight its importance and contribution in these early stages of this disease.
GATA2 and castration-resistant prostate cancer.
Androgen-deprivation therapy (ADT) can be achieved using surgical (bilateral orchiectomy) or chemical castration, and has been considered the frontline therapeutic strategy for locally advanced and metastatic androgendependent prostate cancer for over 40 years 70 . Chemical castration is generally achieved using gonadotropinreleasing hormone (GnRH) agonists, GnRH antagonists, or antiandrogens 70 . ADT has proven to be effective in achieving disease remission and PSA concentration decline in 90% of patients 71 . However, after a mean time of 24-36 months, the disease inexorably evolves to a castratation-resistant state associated with poor prognosis and a short survival time 72 . Increased tumour growth despite only castrate levels of androgens in circulation being present is a hallmark of CRPC 73 . Much experimental evidence demonstrates that AR signalling is enhanced during the development of CRPC 72, 74 ; however, mechanisms of CRPC development that bypass the AR altogether have also been described 74 . Mechanisms of progression towards CRPC include AR hypersensitivity (such as AR amplification), the outlaw AR pathway (including events such as AR activation by receptor tyrosine-protein kinase erbB-2), AR promiscuity Nature Reviews | Urology Figure 2 | Endothelial transcription factor GATA-2 (GATA2) regulates lethal prostate cancer aggressiveness. During prostate cancer progression, GATA2 contributes to disease relapse in early stages of the disease and to the progression to androgen ablation and taxane therapies by promoting prostate cancer cell invasiveness, dissemination, and survival.
(that can be caused by AR mutations that increase binding to nonandrogen steroids) and activation of bypass pathways (such as myc proto-oncogene protein activation) 75 . Notably, altered AR signalling in CRPC is also proposed to occur through several mechanisms that include changes in the expression of co-activators and co-repressors, including increased GATA2 gene and protein expression 67 . The contribution of GATA2 to progression to CRPC is supported by data from a prostate cancer xenograft mouse model of androgen-dependent disease that suggest GATA2 expression levels increase throughout the shift from an androgen-dependent disease status to a castration-resistant one 76 . Moreover, GATA2 levels are higher in hormone-refractory tumour samples than hormone-dependent specimens 59 . Nevertheless, the mechanisms through which GATA2 results in increased AR signalling and translates into cell proliferation and survival in the androgendepleted context are far from being clearly understood. Mechanistically, resistance to androgen deprivation might act in a similar manner to that of androgendependent growth -that is, through the ability of pioneer factors FOXA1 and GATA2 to interact with AR and increase its transcriptional activity 67 . In this context, marked H3K4 histone methylation would recruit these transcription factors and induce AR binding to a set of M-phase cell-cycle, AR-target genes involved in prostate growth 67, 77, 78 . He and colleagues 62 showed that GATA2 regulates AR signalling in CRPC; silencing GATA2 resulted in decreased AR gene and protein expression in LNCaP cells. Notably, exogenous restoration of full-length AR or truncated AR variants failed to restore the activity of AR-regulated genes including PSA, TMPRSS2, and FKBP5 when GATA2 was silenced. Taken together, these results suggest that GATA2 has a key role in maintaining AR signalling activity in CRPC.
Alternative treatment modalities such as taxane therapy (including docetaxel and cabazitaxel) and second-generation androgen inhibitors (for example, enzalutamide) have emerged as therapeutic strategies capable of improving survival of patients with CRPC 21, 79 . However, despite all current therapeutic efforts, the disease can eventually progress to an AR-independent state in which the tumour does not inherently rely on AR signalling. One of the most important pathways that bypasses AR involves the loss of the tumour-suppressor gene PTEN, resulting in the activation of RAC-α serinethreonine-protein kinase (AKT), phosphorylation of Bcl2-associated agonist of cell death (BAD) and, finally, in the release of apoptosis regulator Bcl-2 (REF. 80 ), which triggers cell survival and proliferation. Overexpression of ubiquitin-conjugating enzyme E2 C (UBE2C) has also been observed to drive AR-negative CRPC cell growth and survival in vitro, although the mechanisms that regulate this process have not been fully elucidated 78 . GATA2 seems to be a newly discovered mediator of aggressiveness in AR-negative CRPC cells through the regulation of a signature of cancer-progression-associated genes which include IGF2, PAK4, FOXM1, GLNT7 and ARRDC3 (REF. 59 ). Upregulation of GATA2 is associated with chemotherapy resistance and tumorigenicity in docetaxel-resistant cell lines and progression to lethal disease in men treated with chemotherapy, and GATA2 knockdown resensitizes docetaxel-resistant cell lines to docetaxel and cabazitaxel and increases apoptosis on treatment. In vivo, knockdown of GATA2 in patientderived, castration-resistant, taxane-resistant xenografts generated from circulating tumour cells results in reduced tumour growth 59 . RNA sequencing revealed a signature of 28 GATA2-regulated genes that are associated with cancer development and progression, cell death and survival, and cell growth and proliferation. The genes in this signature were enriched in a population of men who had lethal prostate cancer and men with prostate cancer who had received chemotherapy. Analysis of a subset of these genes showed their expression was unaffected by AR knockdown in vitro suggesting that GATA2 regulates clinically relevant AR-independent genes that contribute to resistance to chemotherapy 59 . Mechanistically, results from GATA2 silencing and overexpression studies demonstrated that it regulates insulin-like growth factor II (IGF2) expression. GATA2 achieves this regulation by directly binding to the IGF2 promoter region and IGF2 then activates a downstream survival polykinase network that renders cells resistant to taxane therapy. The contribution of GATA2 and its effector gene IGF2 to the aggressiveness of late lethal disease stages has been validated in tumour samples from patients; immunohistochemistry showed IGF2 expression increases during the progression of prostate cancer from primary disease to CRPC, and that expression levels are highest in men who have received taxane therapy. Furthermore, increased levels of both GATA2 and IGF2 were associated with poor response to docetaxel treatment in chemotherapy-naive men with CRPC 59 . In summary, study results have unveiled a multifaceted and critical role for GATA2 in driving the aggressiveness of prostate cancer through all the stages of disease. First by enhancing AR signalling through its pioneer transcription factor function in early stage disease, and then by acting as a master regulator that controls a signalling network of effector genes associated with cancer aggressiveness independently of the AR.
Targeting GATA2 in prostate cancer
Targeting GATA2 is a highly attractive therapeutic strategy that might improve the clinical outcome of patients with prostate cancer, owing to its contribution to disease progression and cancer aggressiveness. In particular, inhibition of GATA2 in the context of both CRPC and taxane-resistant prostate cancer would be a valuable and novel alternative strategy to targeting AR signalling independently of androgen ligand binding and also to disrupting the survival signalling network that contributes to the acquisition of taxane resistance. GATA2 blockade could be applicable and beneficial for a broad spectrum of men with prostate cancer in different clinical contexts, ranging from early-stage disease to aggressive CRPC.
To date, attempts to directly target GATA2 have not been pursued and GATA2 continues to be considered an undruggable transcription factor 81 . Indeed, critical information that is required in order to attempt direct targeting of GATA2 has not been gathered. For example, the 3D protein conformational structure of GATA2 (REFS 82,83), which would help identify compounds that bind specific domains and inhibit GATA2 activity, remains to be defined. Despite these limitations, studies investigating the mechanisms that underlie GATA2 expression and its signalling network have been undertaken. Novel therapeutic strategies that inhibit GATA2 activity have been discovered in these studies, which can be divided into the targeting of upstream GATA2 regulators, post-translational and/or epigenetic GATA2 activating mechanisms, and downstream GATA2 effector signalling pathways (FIG. 3) .
Targeting upstream regulatory signalling pathways of GATA2. The NOTCH signalling pathway has been extensively reported to be an upstream regulator of GATA2 activity in the haematopoietic system and to also regulate GATA2 expression in prostate cancer cells [84] [85] [86] [87] [88] [89] . NOTCH signalling controls haemato poietic progenitor cell expansion and differentiation via upregulation of GATA2 expression [84] [85] [86] [87] [88] [89] by directly binding the promoter region of GATA2 and consequently activating its transcription 37 . In prostate cancer cells, NOTCH signalling regulates proliferation, metastasis, and progression [90] [91] [92] [93] . Functionally, the biological effects of NOTCH are mediated directly by activation of the canonical NOTCH pathway and through crosstalk between NOTCH and other pathways such as the PTEN-phosphoinositide 3-kinase (PI3K)-AKT pathway 94 . Indeed, prostate cancer cell aggressiveness properties are considerably increased through activation of the PI3K-AKT pathway by NOTCH 93 .
Results from a 2015 study demonstrated that knockdown of NOTCH2 substantially reduced GATA2 protein levels in chemotherapy-resistant CRPC cells, thereby establishing that GATA2 is a target of NOTCH signalling in prostate Nature Reviews | Urology cancer cells 59 . Considered together, these studies suggest that GATA2 activity can be targeted through inhibition of NOTCH activity. Currently, strategies that target NOTCH signalling, either through anti-NOTCH antibodies or by inhibiting γ secretase activity, are being investigated 95, 96 . Testing the capacity of these therapeutics to inhibit GATA2 activity as a surrogate marker of efficient NOTCH pathway inhibition in prostate cancer could be of particular interest in the future.
Several other upstream pathways have also been reported to regulate GATA2 activity and these pathways also have a key role in the pathogenesis and aggressiveness of prostate cancer [97] [98] [99] [100] [101] [102] [103] [104] . However, the definitive role of these pathways in regulating GATA2 activity in the prostate cancer setting is yet to be investigated. For example, the protein C-ets-1 (ETS) transcription factor potassium voltage-gated channel subfamily H member 2 (ERG), which is known to have a critical role in prostate cancer tumorigenesis 105 , directly regu lates the transcription of GATA2 by binding to its promoter region in embryonic haematopoietic stem cells 97 . Similarly, the ETS1 transcription factor regulates GATA2 expression in haematopoietic progenitor cells 98 . Furthermore, the Hedgehog signalling pathway, which is critical in the pathogenesis of prostate cancer 106 , controls GATA2 expression and considerably effects in the cell fate of neurons 99 , adipocytes 100 and the development of the pituitary gland 101 , therefore, suggesting that Hedgehog signalling could increase prostate cancer aggressiveness through GATA2. Moreover, members of the transforming growth factor β (TGFβ) family activin A, bone morphogenetic protein 2 (BMP2), and BMP4 that have been implicated in the regulation of haematopoiesis have been shown to regulate GATA2 by repressing its transcription [102] [103] [104] . In a mouse model, loss-of-function mutations in TGFβ pathway genes resulted in decreased plasminogen activator inhibitor-1 levels, a downstream target of TGFβ, and was associated with increased prostate tumour grade and metastasis 107 , therefore, suggesting that TGFβ could be regulating the invasiveness properties of prostate cancer cells through GATA2. These data indicate a potential link between the regulation of GATA2 by the TGFβ pathway in prostate cancer development and progression.
In conclusion, many molecules and signalling pathways that are involved in the pathogenesis of prostate cancer also serve as regulators of GATA2 expression. Future studies are warranted to elucidate their specific role in regulating GATA2 expression in the context of prostate cancer and to discover novel targeting approaches that can be implemented as therapeutic measures against this disease.
Targeting post-translational and epigenetic GATA2 activating mechanisms. Post-translational modifications have been extensively implicated in regulating GATA2 activity. For example, acetylation of lysine in the GATA2 protein controls protein structure and function 108 . Acetylation of histone and nonhistone proteins is mediated by histone acetyl transferases (HATs) and histone deacetylases (HDACs) and is paramount to the accessibility of transcription factors such as GATA2 to chromatin. Importantly, GATA2 contains multiple acetylation sites, which are predominantly located in its zinc finger regions 108 . Acetylation of GATA2 mediated by the co-activator histone acetyltransferase p300 (p300)-CREB-binding protein (CBP) enhances its DNA binding activity in haematopoietic precursors and other cell types, such as human kidney epithelial cells and fibroblast-like cells 108, 109 . Furthermore, p300-CBP has a critical role in promoting AR-mediated transcription of prostate cancer associated genes, such as PSA, and prostate cancer progression 110, 111 . Notably, p300 expression levels correlate with those of GATA2 and are highest in aggressive prostate tumours 111 , suggesting that the relationship between GATA2 and AR could be regulated by p300 acetylase activity and providing a rational for modulating GATA2 acetylation status using targeted therapy to reduce its activity in prostate cancer.
Shah and colleagues 112 inhibited p300-CBP HAT activity using the isoflavone compound curcumin and observed decreases in pioneer factor function and AR signalling. Exposure of hormone-dependent and CRPC cells to curcumin did not affect AR protein expression, but did reduce AR signalling activity by decreasing GATA2 and FOXA1 occupancy of PSA and TMPRSS2 enhancer regions. In vivo, treatment of xenografts with curcumin resulted in a considerable decrease in tumour growth in both hormone-dependent and CRPC tumours, an observation that might be explained by the ability of curcumin to interrupt AR signalling in an AR-ligand-independent manner by binding to p300 and inhibiting its activity. Importantly, CRPC xeno grafts that responded to curcumin included those derived from 22Rv1 cells, which have constitutive AR activity and are unresponsive to second-generation antiandrogen therapy. This observation suggests that a disruption in GATA2 acetylation could be a useful thera peutic strategy for targeting prostate cancer tumour cells in which AR signalling continues to be active in a AR-ligand-independent manner.
In the clinical setting, encouraging results have been reported regarding the relevance of curcumin for treating prostate cancer. An initial study showed that curcumin decreased serum PSA concentrations in patients with chronic inflammation of the prostate 113 , and another study showed that men with prostate cancer receiving a dietary supplement containing curcumin experienced a significantly lower rise in serum PSA concentration than patients receiving placebo (P = 0.0008) 114 . Curcumin has shown to be well tolerated 115 and patients have a good response rate to therapy 116 when it is combined with docetaxel therapy; a randomized study is now required to validate these results. Curcumin might synergize with second-generation AR antagonists such as enzalutamide, owing to inhibition of AR signalling through an AR-independent mechanism, and increase the therapeutic window for treating patients with CRPC. However, the clinical bene fits of curcumin could also be attributed to its inherited pleotropic antitumour mechanisms of action (such as inhibition of nuclear factor κ-B (NF-κB) and signal transducer and activator of transcription 3 signalling) or to dietary curcumin supplements that contain other bioactive polyphenols with potential antitumour activity [117] [118] [119] that could disguise or alter the perceived effect of curcumin on tumour progression. Prospective clinical studies that clearly monitor GATA2 activity and subsequent tumour growth when treated with specific curcumin derivatives are needed to ensure that the reported antitumour effect curcumin exhibits are indeed mediated through inhibition of GATA2.
The regulation of GATA2 activity through acetylation has been well documented; however, the role of deacetylation of transcription factors in general and GATA2 in particular is not as well understood. Data suggest that deacetylation might be a general mechanism of GATA2 regulation in human cells, demonstrating that deacetylases HDAC3 and HDAC5 suppress GATA2 transactivation activity in haematopoietic and non tumour cells 109 and that the homopiperazine derivative K-7174 inhibits GATA2 transcriptional activity in hepatoma cells 120 , and HDAC1, HDAC2, and HDAC3 in myeloma cells by inhibiting proteasome acitivity 121 . K-7174 disrupts GATA2 and AR signalling and inhibits hormone-dependent prostate cancer and CRPC growth in vitro and in vivo 62 . K-7174 acts differently in prostate cancer cells from myeloma cells 62 , in which it strongly decreases GATA2 in vitro, suggesting that it acts by decreasing GATA2 protein stability. These data are counterintuitive as K-7174 inhibits HDAC3, which itself represses GATA2. Thus, one would expect K-7174 treatment to result in an increase in GATA2 expression in prostate cancer cells. Further investigation is needed to determine why the effects of K-7174 are different in these different contexts. Interestingly, GATA2 is turned over rapidly through the ubiquitin-proteasome pathway 122 , and F-box and WD repeat domain-containing 7 is an E3 ubiquitin ligase for GATA2 (REF. 123 ) that destabilizes GATA2 and promotes its proteasome degradation, therefore, suggesting a potential mechanism through which K7174 could exert its effects on GATA2 in the context of prostate cancer. However, the mechanism of action of K-7174 remains ill-defined and further studies are needed to identify the clear mechanism of action of this compound in prostate cancer cells.
Similar to acetylation, GATA2 activity can be modulated through phosphorylation. GATA2 phosphorylation occurs via mitogen-activated protein kinase 1 (MAPK) signalling in haematopoietic progenitor cells 124 and the PI3K-AKT signalling pathway in human embryonic kidney cells 125 , different GATA2 phosphory lation sites have differing effects. For example, p38 MAPK phosphorylates GATA2 at serine 192 and activates GATA2 transcription in haematopoietic cells 126, 127 , whereas phosphorylation of serine 401 impairs GATA2 activity by decreasing nuclear translocation and DNA binding in adipocytes 125 . These studies indicate that phosphorylation of GATA2 can regulate its activity in a contextdependent manner. Experimental results from studies in prostate cancer cells suggest that a positive feedback loop exists, whereby activated AKT partially regulates GATA2 expression 59 . Overexpression of constitutively active AKT (myristoylated AKT) increased the mRNA and protein levels of GATA2 in prostate cancer cells, and treatment with the AKT inhibitor MK-2206 reduced GATA expression levels. Treatment with pharmacological inhibitors of AKT resensitized prostate cancer cells to taxane therapy and mimicked the results produced after knockdown of GATA2 expression 59 . Collectively, these studies highlight the potential crosstalk between GATA2 and kinases that control prostate cancer aggressiveness. Additional work is required to characterize the kinases implicated in the phosphory lation of GATA2 and the sites upon which they exert their function, as well as the functional consequences that such post-translational modifications of GATA2 bear in such setting.
GATA2 is rarely mutated or amplified in prostate cancer, which is contrary to observations regarding GATA2 in haematopoietic malignancies [128] [129] [130] , leading to the hypothesis that GATA2 expression can be epigenetically modulated. Methylation is known to have a crucial role in regulating gene expression in cancer cells, and DNA hypomethylation is generally associated with gene activation, whereas hypermethylation is associated to gene silencing. GATA2 expression has been shown to be modulated epigenetically through hypermethy lation and hypomethylation in haematopoietic stem cells 131 and haematopoietic malignancies 132 . A 2015 study reported that the methylation status of GATA2 significantly (P = 0.009) varies between prostate adenoma and prostate cancer samples 133 , suggesting that GATA2 methylation could have a role in the development of prostate cancer. Targeting methylation has proved to be an efficacious clinical therapeutic strategy for a subset of patients diagnosed with myelodysplasia 134 . Thus, further studies are warranted to investigate whether methy lation contributes to GATA2 expression and whether GATA2 can be pharmacologically targeted in prostate cancer through this mechanism.
Targeting GATA2 downstream effector pathways.
Functional studies have identified and characterized the GATA2 gene and protein effectors in the haematopoietic system, lung cancer, and prostate cancer. Some of these effectors can be pharmacologically targeted, offering an opportunity to therapeutically inhibit GATA2 in prostate tumours and reduce their aggressiveness.
GATA2 regulates a well-organized signalling network that operates within the haematopoietic system and includes specific downstream effectors that drive haematopoietic cell fate and malignancy 24, 135, 136 . GATA2 downstream effectors have since been characterized in solid tumours, with Kumar and colleagues 81 describing how GATA2 contributes to the aggressiveness of Krasmutated non-small cell lung cancer (NSCLC) by regulating the activity of the proteasome, IL-1-NF-κB and Rho signalling pathways. Moreover, combined suppression of these GATA2 -regulated pathways in lung cancer cells and in a Kras-mutated mouse model of NSCLC with clinically approved inhibitors bortezomib and/or fasudil resulted in a dramatic inhibition of tumour growth 81 .
Collectively, these results demonstrate that joint inhibition of GATA2 effectors causes substantial regression of Kras-mutated NSCLC. The majority of studies on GATA2 in prostate cancer have focused on its effects on AR effectors, owing to their observed interaction. Promising therapeutic strategies focused on inhibiting GATA2 acetylation are currently in preclinical and clinical development 62, 112 . However, and most importantly within the context of advanced prostate cancer, novel GATA2 effectors independent of AR signalling have been identified 59 . Transcriptome profiling after GATA2 knockdown in docetaxel-resistant cells yielded a signature of GATA2-regulated genes, which was enriched in clinical datasets of advanced prostate cancer and included genes with well-established oncogenic (IGF2, FOXM1) and tumour suppressor (ARRDC3) functions. Some of the cell lines used in this study do not express AR (DU145 and ArCaPM), therefore, this gene set did not include the large number of co-regulated GATA2-AR genes, meaning GATA2 effectors independent of AR could be identified. Mechanistic studies focused on elucidating the regulation of IGF2 by GATA2 showed that GATA2 activates the transcription of IGF2 by directly binding to its promoter, and activation of IGF2 by GATA2 initiates a polykinase survival cascade that enabled prostate cancer cells to survive taxane therapy, among other stressful conditions. IGF2 is a ligand for the insulin-like growth factor 1 receptor (IGF1R) and for the insulin receptor (INSR) 137 , and dual pharmacological inhibition of IGFR1 and INSR using OSI-906 (REF. 138 ) increased taxane sensitivity and overall survival of mice bearing cell-line and patient-derived xenografts 59 . Thus, targeting downstream GATA2 effectors could offer a new therapeutic strategy for treating patients with prostate cancer. GATA2 downstream effectors are not limited to IGF2 and for example include a multitude of metastogenic genes such as ARRDC3, DPYSL3, FOXM1, GALNT7, and PAK4. In addition, GATA2 might regulate the expression of other molecules with unknown implications for cancer, such as the transmembrane nucleoporin nuclear envelope pore membrane protein POM 121 and the postsynaptic protein neurogranin. Thus, mechanistic studies coupled with in vivo validation using preclinical models are strongly warranted to elucidate the function of the most clinically relevant GATA2 effectors that have the potential to be exploited by novel drugs as therapeutic targets to inhibit the lethal progression of advanced prostate cancer.
Conclusions
Therapeutic advances have improved the survival of patients with advanced prostate cancer, but the disease inexorably follows an eventually lethal course. A substantial and growing body of evidence has been gathered suggesting that the pioneer transcription factor GATA2 contributes to the lethality of prostate cancer by enhancing metastatic dissemination of tumour cells and sustaining their survival and progression to standard therapies. The functional and molecular characterization of the mechanisms that activate GATA2 have resulted in the identification of novel potential therapeutic strategies that might delay the progression of this disease. However, from a clinical perspective, implementation of GATA2 targeting in prostate cancer still requires the development of robust and precise predictive assays that identify which patients are most likely to respond to therapy, as well as the rational design of clinical trials in which the combination therapy with the largest therapeutic index is identified.
The prognostic and predictive value of both gene and protein GATA2 expression in patients with prostate cancer indicate that GATA2 is a specific and targetable biomarker of prostate cancer aggressiveness that meets the criteria required for the design of specific detection assays that can be used to drive clinical decisions at the personalized level. Specific assessment of GATA2 activity in prostate cancer specimens from biopsy samples through GATA2 protein immuno staining and gene expression analyses have been developed, are easy to interpret, reproducible, and can be readily implemented into the clinic. In addition, the implications of targeting GATA2 have tremendous potential from a personalized medicine perspective, as it is a prognostic biomarker with predictive value for determining response to standard therapies, and is potentially targetable using novel therapeutic interventions such as GATA2 inhibitors. In this context, the therapeutic development of selective potent GATA2 inhibitory agents will have to meet the criteria for safety and will have to proceed with caution, especially in the context of preventing dose-limiting haematological toxicities, as GATA2 is known to be active in normal haematopoietic stem cells.
The anticipation of potential toxicities might favour the rational design of clinical trials testing combination strategies with standard therapies that do not increase the risk of severe haematologic toxicities, such as second-generation antiandrogen agents. In this context, notably, curcumin, which inhibits GATA2 activity in preclinical models of prostate cancer, was well tolerated in a phase II study when given in combination with the myeloablative taxane agent docetaxel in patients with prostate cancer, suggesting that taxane myelosuppressive effects are not enhanced when GATA2 inhibitors are used concomitantly. Despite these results, care and effort should be taken in the development of novel GATA2 inhibitors and these toxicity-related limitations acknowledged. The design of phase I clinical trials for GATA2 inhibitors should include close monitoring of this potential dose-limiting toxicity. Altogether, the translation of GATA2 inhibitors into the clinic will require the development and validation of new precise prognostic and predictive assays that measure GATA2 expression and the anticipation of toxicities specific to GATA2 inhibition in the design of clinical trials.
In summary, the molecular and functional characterization of GATA2 in prostate cancer has advanced the understanding of the development and progression of this disease and might result in improved stratification of patients with prostate cancer with regards to prognosis and response to standard therapy, as well as novel treatment approaches that might improve the survival of men with prostate cancer.
